AIA
TBPH icon

Allegis Investment Advisors’s Theravance Biopharma TBPH Stock Holding History

Allegis Investment Advisors’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-7
Closed – – 826
2015
Q4 		$0 Buy
+7
New +$111 ﹤0.01% 1141

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Allegis Investment Advisors's TBPH Position: Q1 2016 in Review

Allegis Investment Advisors sold out of Theravance Biopharma (TBPH) in Q1 2016, closing a stake of 7 shares.

Allegis Investment Advisors first reported a position in TBPH in Q4 2015 and held it in 1 quarter. The position peaked at $0 in Q4 2015. 81 funds tracked by Wall St. Rank hold TBPH as of Q1 2016.

  • Allegis Investment Advisors reported no remaining Theravance Biopharma position as of Q1 2016 after selling out during the quarter.
  • Allegis Investment Advisors sold 7 Theravance Biopharma shares in Q1 2016.
  • Allegis Investment Advisors first reported a position in Theravance Biopharma in Q4 2015 and held it in 1 quarter.
  • Allegis Investment Advisors's Theravance Biopharma position peaked at $0 in Q4 2015.
  • 81 funds tracked by Wall St. Rank held Theravance Biopharma as of Q1 2016.

Based on Allegis Investment Advisors's 13F filing for Q1 2016, filed 9 May 2016.